Capricor Therapeutics Inc (CAPR) concluded trading on Thursday at a closing price of $9.56, with 4.79 million shares of worth about $45.79 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -51.07% during that period and on May 15, 2025 the price saw a gain of about 24.64%. Currently the company’s common shares owned by public are about 45.68M shares, out of which, 40.12M shares are available for trading.
Stock saw a price change of 37.16% in past 5 days and over the past one month there was a price change of -2.65%. Year-to-date (YTD), CAPR shares are showing a performance of -30.72% which increased to 75.74% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.52 but also hit the highest price of $23.40 during that period. The average intraday trading volume for Capricor Therapeutics Inc shares is 1.90 million. The stock is currently trading -8.36% below its 20-day simple moving average (SMA20), while that difference is down -12.71% for SMA50 and it goes to -23.47% lower than SMA200.
Capricor Therapeutics Inc (NASDAQ: CAPR) currently have 45.68M outstanding shares and institutions hold larger chunk of about 38.55% of that.
The stock has a current market capitalization of $436.67M and its 3Y-monthly beta is at 0.79. It has posted earnings per share of -$1.42 in the same period. It has Quick Ratio of 6.55 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CAPR, volatility over the week remained 18.18% while standing at 13.48% over the month.
Stock’s fiscal year EPS is expected to rise by 63.57% while it is estimated to decrease by -3.32% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Piper Sandler on October 21, 2024 offering an Overweight rating for the stock and assigned a target price of $35 to it. Coverage by Oppenheimer stated Capricor Therapeutics Inc (CAPR) stock as an Outperform in their note to investors on May 17, 2024, suggesting a price target of $14 for the stock. On January 05, 2024, Cantor Fitzgerald Initiated their recommendations, while on October 26, 2022, Ladenburg Thalmann Initiated their ratings for the stock with a price target of $15. Stock get a Hold rating from Maxim Group on December 26, 2018.
